107 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
EC Ecopetrol S.A. $25.79 $53.02B Downtrend
Article Searches
Changes To Rules Sought After EC Rejects Siemens/Alstom Rail Merger http://feeds.benzinga.com/~r/benzinga/~3/jXz47VKeC7U/changes-to-rules-sought-after-ec-rejects-siemensalstom-rail-merger Feb 06, 2019 -

Germany will seek a reform of European Union (EU) competition regulations following the decision by the European Competition Directorate to reject Siemens' and Alstom's application to merge their rail businesses.

read more

Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs http://www.zacks.com/stock/news/348985/biotech-stock-roundup-amgen-vertex-get-ec-nod-for-label-expansion-of-drugs?cid=CS-ZC-FT-348985 Jan 23, 2019 - A low key week for the biotech sector with regular drug approvals and pipeline updates.
Albireo granted Orphan Designation by EC for A4250 for treatment of biliary atresia https://seekingalpha.com/news/3417836-albireo-granted-orphan-designation-ec-a4250-treatment-biliary-atresia?source=feed_news_all Dec 18, 2018 - Albireo Pharma (NASDAQ:ALBO) announces the European Commission (EC) has granted orphan designation to A4250, an ileal bile acid transporter inhibitor, for the treatment of biliary atresia, a
EC OK's self-administration of Novartis' Xolair across all indications https://seekingalpha.com/news/3416676-ec-oks-self-administration-novartis-xolair-across-indications?source=feed_news_all Dec 13, 2018 - The European Commission (EC) has approved Novartis' (NYSE:NVS) Xolair (omalizumab) prefilled syringe for self-administration for patients with severe allergic asthma and chronic spontaneous ur
The Zacks Analyst Blog Highlights: Royal Dutch, Par Pacific, Precision Drilling, Petrobras and Ecopetrol http://www.zacks.com/stock/news/341269/the-zacks-analyst-blog-highlights-royal-dutch-par-pacific-precision-drilling-petrobras-and-ecopetrol?cid=CS-ZC-FT-341269 Dec 05, 2018 - The Zacks Analyst Blog Highlights: Royal Dutch, Par Pacific, Precision Drilling, Petrobras and Ecopetrol
Oil & Gas Stock Roundup: Shell's Green Initiative, Par Pacific's Acquisition & More http://www.zacks.com/stock/news/341123/oil-gas-stock-roundup-shells-green-initiative-par-pacifics-acquisition-more?cid=CS-ZC-FT-341123 Dec 04, 2018 - Royal Dutch Shell (RDS.A) became the first oil company to link executive pay with carbon emissions, while Par Pacific Holdings (PARR) entered into an acquisition to bolster its downstream operations.
The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings http://feeds.benzinga.com/~r/benzinga/~3/2GrT5jG_15A/the-daily-biotech-pulse-ec-nod-for-shire-mirati-gets-fda-clearance-fo Nov 30, 2018 -

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peak

(Biotech stocks hitting 52-week highs on Nov. 29)

read more

Novartis (NVS) Receives EC Approval for Neulasta Biosimilar http://www.zacks.com/stock/news/339870/novartis-nvs-receives-ec-approval-for-neulasta-biosimilar?cid=CS-ZC-FT-339870 Nov 28, 2018 - Novartis (NVS) obtains EC approval for Ziextenzo, the biosimilar of Amgen's Neulasta.
Stock Market News For Nov 28, 2018 http://www.zacks.com/stock/news/339739/stock-market-news-for-nov-28-2018?cid=CS-ZC--339739 Nov 28, 2018 - Wall Street closed sharply higher on Tuesday after comments from a top U.S. economic adviser raised hopes for a solution to the ongoing trade war with China
EC approves Spark Therapeutics’ LUXTURNA for inherited retinal disease caused by confirmed biallelic RPE65 mutations https://seekingalpha.com/news/3411807-ec-approves-spark-therapeutics-luxturna-inherited-retinal-disease-caused-confirmed-biallelic?source=feed_news_all Nov 23, 2018 - Spark Therapeutics (NASDAQ:ONCE) announces that the European Commission (EC) has granted marketing authorization for LUXTURNA (voretigene neparvovec), a one-time gene therapy for the treatmen

Pages: 12345678...11

<<<Page 3>